Navigation Links
Taligen Therapeutics Secures Series B Financing
Date:2/1/2008

AURORA, Colo., Feb. 1 /PRNewswire/ -- Taligen Therapeutics, Inc. today announced it anticipates receiving up to $65 million in a tranched Series B financing. The financing was led by Alta Partners and Clarus Ventures with participation from existing investors, including Sanderling Ventures, Tango and High Country Venture.

"This Series B round represents not only an infusion of capital but the addition of two world class investor groups, Alta Partners and Clarus Ventures, represented on our Board respectively by Edward Hurwitz and Nicholas Galakatos, PhD," said Timothy Mills, PhD, Chairman of the Board of Taligen. "The progress made since our original investment in 2005 now allows us to develop multiple products to control the alternative pathway of complement activation. With this additional funding, we expect to move into clinical development with all of our lead candidates."

About Taligen: Founded in 2004, Taligen Therapeutics, Inc. is a development-stage biotechnology company with novel technology and expertise focused on modulation and control of the complement system. The complement system is believed to be a critical component in the initiation of inflammation. Complement system activation is characteristic of many human diseases, including asthma, macular degeneration, rheumatoid arthritis and immune renal disease.

Taligen's lead products are monoclonal antibodies and recombinant fusion proteins which target key factors in the alternative complement pathway. These products are in preclinical stages of development to treat systemic as well as local inflammatory conditions.

The Company was founded by Drs. Woodruff Emlen and V. Michael Holers based on technology and intellectual property predominantly from the University of Colorado at Denver and Health Sciences Center (UCDHSC) and partnering institutions. Dr. Holers is currently Professor of Medicine at UCDHSC and Dr. Emlen is a former Professor of Medicine and Immunology at U
'/>"/>

SOURCE Taligen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
3. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
4. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
5. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
6. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
10. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
11. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... Calbiotech, Inc. announced today ...ve Research (SBIR) Phase I contract by the U.S. Ar...rms of the agreement, Calbiotech will develop anal...Dengue virus. ,, Dengue virus is a mosquito-...military forces deployed to tropical areas of the ...
(Date:11/6/2009)...a for Arrowhead’s 2010 Personalized Medicine...ce on February 22-24, 2010 in Philadelphia, has be... highlight key issues in forming partnerships and ...s. , Minneapolis, MN (PRW...squo;s 2010 Personalized Medicine Partnerships Co...
(Date:11/5/2009)...Newswire/ -- The endangered black-footed ferrets i... rare carnivore feeds on prairie dogs. The prair...ntire population die-offs in towns occur. The U.S...d a ferret breeding program and has been releasing...ve habitat. Unfortunately, plague can sweep throu...
(Date:11/5/2009)...5 ThermoGenesis Corp. (N...roducts for processing and storing adult stem cell... fiscal 2010. ,, For the quarter ended Septembe...million, a 15 percent increase over revenues of $4...mpany said the key contributors to the growth in r...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
...0 split ratio, SEATTLE, Aug. 25 Cell Therapeutic...t its Board of Directors has,authorized a 1-for-10...lit,will become effective as of August 31, 2008., ...of Annual Meeting of,Shareholders held on June 19,...ze the Board, in its discretion, to effect a rever...
...kman,Coulter, Inc. (NYSE: BEC ), a leading develo...implify, automate, and innovate complex biomedical...kman Coulter,s senior vice,president and chief fin...Healthcare Conference 2008 on Thursday, September ...wscom.com/cgi-bin/prnh/20031202/BECLOGO ), The li...
...nd business expertise, SCOTTSDALE, Ariz., Aug. 22...company that markets the Provant(R) Wound Therapy,...s to its Board of,Directors. The two new directors...harmaceuticals, and Charles "Chuck" S. Lunden, a p...://www.newscom.com/cgi-bin/prnh/20080422/LATU008 )...
Other Biology Technology:Cell Therapeutics, Inc. Announces Reverse Stock Split 2Regenesis Biomedical Announces Additions to Board of Directors 2
(Date:11/6/2009)... generally live in harmony with their arboreal hos...ut of space in their trees of choice, the ants can...earch, published in the November issue of the Ame...nts bore into live trees, and it reopens a centuri... plants. , Ants and certain species of plants an...
(Date:11/5/2009)...searchers at Yale University have developed synthe...ne response to HIV and HIV-infected cells, as well...ished online in the Journal of the American Chemi...oaches for these diseases. , The molecules cal...ARM-H) and "antibody-recruiting molecule targeting...
(Date:11/4/2009)...idors in the cities of Long Beach and Riverside ar...entable childhood asthma, and the true impact of a... likely been underestimated, according to research.... , The study, which appears in an online editi...imated that nine percent of all childhood asthma c...
Breaking Biology News(10 mins):Ants are friendly to some trees, but not others 2New synthetic molecules trigger immune response to HIV and prostate cancer 2USC study finds big air pollution impacts on local communities 2Kaiser Workers Statewide Campaign Starts Tuesday 55751 1Kaiser Workers Statewide Campaign Starts Tuesday 55751 2CPF Submits Comments to CMS to Save Only Effective Therapy Available to PF Patients 55748 1CPF Submits Comments to CMS to Save Only Effective Therapy Available to PF Patients 55748 2CPF Submits Comments to CMS to Save Only Effective Therapy Available to PF Patients 55748 3CPF Submits Comments to CMS to Save Only Effective Therapy Available to PF Patients 55748 4CPF Submits Comments to CMS to Save Only Effective Therapy Available to PF Patients 55748 5VirtualScopics to Present at the Rodman 26 Renshaw Annual Global Investment Conference 55746 1VirtualScopics to Present at the Rodman 26 Renshaw Annual Global Investment Conference 55746 2
...E, Fla. Replacing one amino acid on the surface o...ls could be the breakthrough scientists have neede...eating genetic diseases such as hemophilia, Univer...he journal Proceedings of the National Academy of ...ave developed a new version of the adeno-associate...
...bout water quality at beaches along the Great Lake... waters are safe for recreation. A new collaborati...each managers when they are faced with deciding wh...his collaborative effort will draw on the expertis...te and local agencies. , The project has been fu...
...WA The inland areas of the Pacific Northwest, whe... present growing challenges for vineyard owners an...s part of the country have not been conducive for ...y wine grapes. , To promote healthy grape product...s in the area typically employ an irrigation pract...
Other Biology News:UF researchers develop improved gene therapy agent 2UF researchers develop improved gene therapy agent 3To swim or not to swim? 2Study results: new recommendations for grape growers 2
...ystem - dUTP with CyScribe GFX Purification Kit, 5...f Cy3- and Cy5-labeled cDNA.Optimized reagents are...purification.Flexible and optimized protocols can ...her Cy3- or Cy5-labeled nucleotides.Reliable purif...
Canine serum from Equitech-Bio
Rabbit Anti-TOLLIP Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
... mA, 100 W maximum.Constant voltage, constant curr...ts in settings and read-outs for precision and rep...tstanding choice for non-IEF ultrathin flatbed gel...Electrophoresis Systems & Standards & Reagents, Po...
Biology Products: